The European Patent Office recommends grant of a new patent covering a key ingredient in ColdZyme against the common cold
The European Patent Office has issued a notice of allowance indicating its intention to grant a patent for a key cod enzyme component of Enzymatica’s mouth spray ColdZyme for treatment of the common cold. The expected patent will be valid until 2035. The final grant for Europe is expected in summer 2020 following completion of the grant formalities. This grant will represent the first patent in a family that covers all major health care markets in the world.“The new patent extends protection for ColdZyme and other Enzymatica products based on the same technology platform for another 15